Latest Pioglitazone Stories
Diabetic patients who develop bladder cancer after taking the drug Actos (pioglitazone) tend to have about the same number of Stage I, II, and III cancers as surgical patients who never used Actos.
Research on more than 11,000 Korean users of the diabetes drug pioglitazone finds that smaller doses are no protection against bladder cancer. Raleigh, NC (PRWEB)
Taiwanese author says his research should relieve concern among diabetics that insulin might raise their cancer risk. Raleigh, NC (PRWEB) February 19, 2014
Scientists find a “modest but clinically significant” link between the diabetes drug and bladder cancer. Raleigh, NC (PRWEB) February 17, 2014 The
Researchers say the diabetes drug does not appear to reduce the risk of bladder cancer in patients with type 2 diabetes. Raleigh, NC (PRWEB) February 14, 2014
National network of attorneys is providing consumer updates and no-cost consultations over allegations that the use of the diabetes medication Actos can cause patients to develop bladder cancer.
On January 27, a federal Judge ruled that Takeda acted in “bad faith” and destroyed relevant evidence to the Actos Multidistrict Litigation.
The Firm is filing Actos lawsuits on behalf of individuals who took Actos for an extended period of time, and allegedly developed bladder cancer due to their use of the Type 2 diabetes medication.
Schlichter, Bogard & Denton, LLP is investigating and pursuing claims on behalf of individuals who allege that they have been diagnosed with bladder cancer after taking the diabetes medication
First Actos bellwether trial is underway, with the jury having been selected on Monday.
- A person in a secondary role, specifically the second most important character (after the protagonist).